Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats

Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats

Synaptic dysfunction is hypothesised to play a key role in schizophrenia pathogenesis. Here, using [11C]UCB-J PET, the authors show for the first time in vivo that levels of the synaptic marker protein SV2A are reduced in schizophrenia and unaffected by antipsychotic treatment in a rat model.

Saved in:
Bibliographic Details
Main Authors: Ellis Chika Onwordi, Els F. Halff, Thomas Whitehurst, Ayla Mansur, Marie-Caroline Cotel, Lisa Wells, Hannah Creeney, David Bonsall, Maria Rogdaki, Ekaterina Shatalina, Tiago Reis Marques, Eugenii A. Rabiner, Roger N. Gunn, Sridhar Natesan, Anthony C. Vernon, Oliver D. Howes
Format: article
Language:EN
Published: Nature Portfolio 2020
Subjects:
Science
Q
Online Access:https://doaj.org/article/d2e6a5e593d0405db0ad2d55f3b35447
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/d2e6a5e593d0405db0ad2d55f3b35447

Similar Items